Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F16%3A43875545" target="_blank" >RIV/60162694:G44__/16:43875545 - isvavai.cz</a>
Result on the web
<a href="http://www.sciencedirect.com/science/article/pii/S0264410X15013493" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0264410X15013493</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.vaccine.2015.09.073" target="_blank" >10.1016/j.vaccine.2015.09.073</a>

Result language
angličtina
Original language name
Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults
Original language description
An investigational subunit vaccine containing the varicella-zoster virus (VZV) glycoprotein E (gE) and the AS01B adjuvant system is being evaluated for the prevention of herpes zoster (HZ) in older adults. A phase II trial evaluating different formulations of this vaccine (containing 25 μg, 50 μg, or 100 μg gE) was conducted in adults GREATER-THAN OR EQUAL TO60 years of age and showed that all formulations elicited robust cellular and humoral immune responses for up to 3 years after vaccination. In this follow-up study in subjects who received two doses of the 50 μg gE/AS01B formulation (HZ/su), we assessed the persistence of the immune responses for up to 6 years after vaccination.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FN - Epidemiology, infection diseases and clinical immunology
OECD FORD branch
—

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)